Pharmafile Logo
Pharmafocus logo
Advanced Search

NSCLC

Showing 15 posts of 132 posts found.

Tarceva image

NICE final yes for Zytiga and Tarceva

June 27, 2012
Sales and Marketing Janssen, NHS, NICE, NSCLC, Roche, Tarceva, Zytiga

In final guidance published today, NICE is recommending two new drugs for patients with prostate and lung cancer. Janssen’s Zytiga …

News
Tarceva image

Discount sways NICE into recommending Tarceva

May 10, 2012
Sales and Marketing Iressa, NICE, NSCLC, Roche, Tarceva, lung cancer

NICE is recommending Roche’s lung cancer pill Tarceva in patients with a certain type of the disease.  The watchdog said …

News

DSM sees green shoots for pharma unit in Q1

May 8, 2012
Business Services, Manufacturing and Production, Sales and Marketing DSM, Kensey Nash, NSCLC, Q1, Sinochem

DSM said its pharmaceutical business unit posted ‘weak’ financials in the first quarter of 2012, although revenues rose and there …

News
Merck image

Merck does cancer drug deal with Endocyte

April 17, 2012
Research and Development, Sales and Marketing Cancer, Endocyte, Merck, NSCLC, vintafolide

Merck is to pay $120 million to US biopharma company Endocyte as part of a deal to develop and commercialise …

News
Roche's Tarceva (erlotinib)

Tarceva approval for first-line use in EGFR lung cancer

September 1, 2011
Sales and Marketing NSCLC, Roche, Tarceva

Tarceva has been granted final European approval for patients with a genetically distinct type of non-small cell lung cancer (NSCLC). …

News

Tarceva impresses again as it seeks to extend its EU licence

June 3, 2011
NSCLC, Roche, Tarceva

Roche and its partner OSI Pharmaceuticals have released another series of positive results for its lung cancer drug Tarceva as …

News

Pfizer files lung cancer drug in US and Japan

May 18, 2011
Sales and Marketing NSCLC, Pfizer, crizotinib

Pfizer has submitted its oral lung cancer drug crizotinib for regulatory approval in the US and Japan. Crizotinib is an …

News
Amgen

Amgen’s novel lung cancer drug disappoints in phase III

April 1, 2011
Research and Development Amgen, Millennium, NSCLC, Takeda, motesanib, non-small cell lung cancer

Amgen’s lung cancer drug motesanib has not meet its primary endpoint in a phase III study. The drug, developed in …

News
Erbitux (cetixumab)

Merck re-submits Erbitux to the EMA for lung cancer

March 30, 2011
Sales and Marketing EGFR, Erbitux, Iressa, Merck KGaA, NSCLC, Tarceva, lung cancer drugs, non-small cell lung cancer

Merck KGaA has re-submitted Erbitux’s lung cancer licence extension to the EMA after its first application to the regulator was …

News

Sanofi lung cancer drug fails in late-stage trial

March 11, 2011
Research and Development Cancer, NSCLC, Regeneron, Sanofi-Aventis, aflibercept, non-small cell lung cancer

Sanofi-Aventis’ lung cancer drug aflibercept has failed to meet its primary endpoint in a phase III trial. The late-stage VITAL …

News
Lung cancer cells

No magic bullet, but a growing arsenal against lung cancer

February 23, 2011
Research and Development ASA404, Cancer, Iressa, NSCLC, Tarceva, afatinib, crizotinib, figitumumab, lung cancer, non small cell lung cancer, non-small cell lung cancer

A man in his 70s is waiting for his appointment with the oncologist after being referred there by his family …

Feature

Blood clot fears halt cancer trial enrolment

February 3, 2011
Research and Development BMS, Bristol-Myers Squibb, Eli Lilly, NSCLC, lilly, necitumumab, non small cell lung cancer, non-small cell lung cancer

Lilly and BMS have stopped enrolment in a phase III trial of necitumumab, a new treatment for non-small cell lung …

News

Tarceva set for first line treatment

January 31, 2011
Sales and Marketing Iressa, NSCLC, Roche, Tarceva

Roche’s lung cancer treatment Tarceva has been shown to help patients as a first line treatment. An independent data monitoring …

News
Pfizer's Lipitor tablet

Pfizer lung cancer drug gets ‘rolling’ fast-track status in US

January 13, 2011
Sales and Marketing Cancer, NSCLC, axitinib, bosutinib, crizotinib, non-small cell lung cancer

Pfizer has initiated a ‘rolling’ submission for its new oral ALK lung cancer drug crizotinib that could see it on …

News

Roche to develop diagnostic tools for Tarceva

November 23, 2010
Sales and Marketing Genzyme, NSCLC, Roche, Tarceva, diagnostic

Roche has obtained a worldwide sub-license from Genzyme to develop a diagnostic kit for the detection of specific mutations for …

News

Latest content

OSE Immunotherapeutics and Boehringer Ingelheim collaborate on cancer and cardio-renal-metabolic disease treatments

May 24, 2024

Nona Biosciences announced agreement with AstraZeneca for tumour targeted therapies

May 24, 2024

BioGen to acquire Human Immunology Biosciences for $1.15bn

May 23, 2024

Merck to acquire Mirus Bio for $600m

May 23, 2024

Rare disease clinical trials: the urgent need for patients to be heard

May 22, 2024